A Single Dose BE Study of X-396 in Healthy Volunteers Under Fasted Conditions
Status:
Not yet recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase I single dose 2-part, crossover bioequivalence study under
fasted conditions. The trial is designed to evaluate the pharmacokinetic parameters between
single doses of 100mg ensartinib capsules manufactured by two difference processes.